Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Neuroinflammation
Published in: Journal of Neuroinflammation 1/2014

Open Access 01-12-2014 | Review

Calcineurin and glial signaling: neuroinflammation and beyond

Authors: Jennifer L Furman, Christopher M Norris

Published in: Journal of Neuroinflammation | Issue 1/2014

Login to get access

Abstract

Similar to peripheral immune/inflammatory cells, neuroglial cells appear to rely on calcineurin (CN) signaling pathways to regulate cytokine production and cellular activation. Several studies suggest that harmful immune/inflammatory responses may be the most impactful consequence of aberrant CN activity in glial cells. However, newly identified roles for CN in glutamate uptake, gap junction regulation, Ca2+ dyshomeostasis, and amyloid production suggest that CN’s influence in glia may extend well beyond neuroinflammation. The following review will discuss the various actions of CN in glial cells, with particular emphasis on astrocytes, and consider the implications for neurologic dysfunction arising with aging, injury, and/or neurodegenerative disease.
Appendix
Available only for authorised users
Literature
1.
Musson RE, Smit NP: Regulatory mechanisms of calcineurin phosphatase activity. Curr Med Chem. 2011, 18: 301-315.PubMed
2.
Baumgartel K, Mansuy IM: Neural functions of calcineurin in synaptic plasticity and memory. Learn Mem. 2012, 19: 375-384.PubMed
3.
Norris CM: Calpain interactions with the protein phosphatase calcineurin in neurodegeneration. Adv Biochem Health Dis. 2014, 8: 17-45.
4.
Stemmer PM, Klee CB: Dual calcium ion regulation of calcineurin by calmodulin and calcineurin B. Biochemistry. 1994, 33: 6859-6866.PubMed
5.
Klee CB, Ren H, Wang X: Regulation of the calmodulin-stimulated protein phosphatase, calcineurin. J Biol Chem. 1998, 273: 13367-13370.PubMed
6.
Goto S, Matsukado Y, Mihara Y, Inoue N, Miyamoto E: The distribution of calcineurin in rat brain by light and electron microscopic immunohistochemistry and enzyme-immunoassay. Brain Res. 1986, 397: 161-172.PubMed
7.
Goto S, Matsukado Y, Mihara Y, Inoue N, Miyamoto E: Calcineurin in human brain and its relation to extrapyramidal system. Immunohistochemical study on postmortem human brains. Acta Neuropathol. 1986, 72: 150-156.PubMed
8.
Kuno T, Mukai H, Ito A, Chang CD, Kishima K, Saito N, Tanaka C: Distinct cellular expression of calcineurin A alpha and A beta in rat brain. J Neurochem. 1992, 58: 1643-1651.PubMed
9.
Polli JW, Billingsley ML, Kincaid RL: Expression of the calmodulin-dependent protein phosphatase, calcineurin, in rat brain: developmental patterns and the role of nigrostriatal innervation. Brain Res Dev Brain Res. 1991, 63: 105-119.PubMed
10.
Halpain S, Girault JA, Greengard P: Activation of NMDA receptors induces dephosphorylation of DARPP-32 in rat striatal slices. Nature. 1990, 343: 369-372.PubMed
11.
Halpain S, Greengard P: Activation of NMDA receptors induces rapid dephosphorylation of the cytoskeletal protein MAP2. Neuron. 1990, 5: 237-246.PubMed
12.
13.
Abdul HM, Furman JL, Sama MA, Mathis DM, Norris CM: NFATs and Alzheimer’s disease. Mol Cell Pharmacol. 2010, 2: 7-14.PubMedCentralPubMed
14.
Vinade L, Goncalves CA, Wofchuk S, Gottfried C, Rodnight R: Evidence for a role for calcium ions in the dephosphorylation of glial fibrillary acidic protein (GFAP) in immature hippocampal slices and in astrocyte cultures from the rat. Brain Res Dev Brain Res. 1997, 104: 11-17.PubMed
15.
Matsuda T, Takuma K, Asano S, Kishida Y, Nakamura H, Mori K, Maeda S, Baba A: Involvement of calcineurin in Ca2+paradox-like injury of cultured rat astrocytes.J Neurochem 1998, 70:2004-2011..
16.
Hashimoto T, Kawamata T, Saito N, Sasaki M, Nakai M, Niu S, Taniguchi T, Terashima A, Yasuda M, Maeda K, Tanaka C: Isoform-specific redistribution of calcineurin A alpha and A beta in the hippocampal CA1 region of gerbils after transient ischemia. J Neurochem. 1998, 70: 1289-1298.PubMed
17.
Ferrari D, Stroh C, Schulze-Osthoff K: P2X7/P2Z purinoreceptor-mediated activation of transcription factor NFAT in microglial cells. J Biol Chem. 1999, 274: 13205-13210.PubMed
18.
Norris CM, Kadish I, Blalock EM, Chen KC, Thibault V, Porter NM, Landfield PW, Kraner SD: Calcineurin triggers reactive/inflammatory processes in astrocytes and is upregulated in aging and Alzheimer’s models. J Neurosci. 2005, 25: 4649-4658.PubMedCentralPubMed
19.
Abdul HM, Sama MA, Furman JL, Mathis DM, Beckett TL, Weidner AM, Patel ES, Baig I, Murphy MP, LeVine H, Kraner SD, Norris CM: Cognitive decline in Alzheimer’s disease is associated with selective changes in calcineurin/NFAT signaling. J Neurosci. 2009, 29: 12957-12969.PubMedCentralPubMed
20.
Celsi F, Svedberg M, Unger C, Cotman CW, Carri MT, Ottersen OP, Nordberg A, Torp R: Beta-amyloid causes downregulation of calcineurin in neurons through induction of oxidative stress. Neurobiol Dis. 2007, 26: 342-352.PubMed
21.
Lim D, Iyer A, Ronco V, Grolla AA, Canonico PL, Aronica E, Genazzani AA: Amyloid beta deregulates astroglial mGluR5-mediated calcium signaling via calcineurin and Nf-kB. Glia. 2013, 61: 1134-1145.PubMed
22.
Verkhratsky A, Sofroniew MV, Messing A, deLanerolle NC, Rempe D, Rodriguez JJ, Nedergaard M: Neurological diseases as primary gliopathies: a reassessment of neurocentrism. ASN Neuro. 2012, 4 (3): e00082.PubMedCentralPubMed
23.
Schousboe A, Waagepetersen HS: Role of astrocytes in glutamate homeostasis: implications for excitotoxicity. Neurotox Res. 2005, 8: 221-225.PubMed
24.
Maragakis NJ, Rothstein JD: Mechanisms of disease: astrocytes in neurodegenerative disease. Nat Clin Pract Neurol. 2006, 2: 679-689.PubMed
25.
Eugenin EA, Basilio D, Saez JC, Orellana JA, Raine CS, Bukauskas F, Bennett MV, Berman JW: The role of gap junction channels during physiologic and pathologic conditions of the human central nervous system. J Neuroimmune Pharmacol. 2012, 7: 499-518.PubMedCentralPubMed
26.
Parpura V, Heneka MT, Montana V, Oliet SH, Schousboe A, Haydon PG, Stout RF, Spray DC, Reichenbach A, Pannicke T, Pekny M, Pekna M, Zorec R, Verkhratsky A: Glial cells in (patho)physiology. J Neurochem. 2012, 121: 4-27.PubMedCentralPubMed
27.
28.
Pekny M, Nilsson M: Astrocyte activation and reactive gliosis. Glia. 2005, 50: 427-434.PubMed
29.
Sofroniew MV: Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci. 2009, 32: 638-647.PubMedCentralPubMed
30.
Pekny M, Wilhelmsson U, Pekna M: The dual role of astrocyte activation and reactive gliosis. Neurosci Lett. 2014, 565: 30-38.PubMed
31.
Akama KT, Albanese C, Pestell RG, Van Eldik LJ: Amyloid beta-peptide stimulates nitric oxide production in astrocytes through an NFkappaB-dependent mechanism. Proc Natl Acad Sci U S A. 1998, 95: 5795-5800.PubMedCentralPubMed
32.
Keene SD, Greco TM, Parastatidis I, Lee SH, Hughes EG, Balice-Gordon RJ, Speicher DW, Ischiropoulos H: Mass spectrometric and computational analysis of cytokine-induced alterations in the astrocyte secretome. Proteomics. 2009, 9: 768-782.PubMedCentralPubMed
33.
Sama MA, Mathis DM, Furman JL, Abdul HM, Artiushin IA, Kraner SD, Norris CM: Interleukin-1beta-dependent signaling between astrocytes and neurons depends critically on astrocytic calcineurin/NFAT activity. J Biol Chem. 2008, 283: 21953-21964.PubMedCentralPubMed
34.
Fuller S, Steele M, Munch G: Activated astroglia during chronic inflammation in Alzheimer’s disease-do they neglect their neurosupportive roles?. Mutat Res. 2010, 690: 40-49.PubMed
35.
Carter SF, Scholl M, Almkvist O, Wall A, Engler H, Langstrom B, Nordberg A: Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. J Nucl Med. 2012, 53: 37-46.PubMed
36.
Owen JB, Di Domenico F, Sultana R, Perluigi M, Cini C, Pierce WM, Butterfield DA: Proteomics-determined differences in the concanavalin-A-fractionated proteome of hippocampus and inferior parietal lobule in subjects with Alzheimer’s disease and mild cognitive impairment: implications for progression of AD. J Proteome Res. 2009, 8: 471-482.PubMedCentralPubMed
37.
Schipper HM, Bennett DA, Liberman A, Bienias JL, Schneider JA, Kelly J, Arvanitakis Z: Glial heme oxygenase-1 expression in Alzheimer disease and mild cognitive impairment. Neurobiol Aging. 2006, 27: 252-261.PubMed
38.
Crabtree GR, Olson EN: NFAT signaling: choreographing the social lives of cells. Cell. 2002, 109 (Suppl): S67-S79.PubMed
39.
Horsley V, Pavlath GK: NFAT: ubiquitous regulator of cell differentiation and adaptation. J Cell Biol. 2002, 156: 771-774.PubMedCentralPubMed
40.
Rao A, Luo C, Hogan PG: Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol. 1997, 15: 707-747.PubMed
41.
Liou HC, Baltimore D: Regulation of the NF-kappa B/rel transcription factor and I kappa B inhibitor system. Curr Opin Cell Biol. 1993, 5: 477-487.PubMed
42.
Palkowitsch L, Marienfeld U, Brunner C, Eitelhuber A, Krappmann D, Marienfeld RB: The Ca2 + -dependent phosphatase calcineurin controls the formation of the Carma1-Bcl10-Malt1 complex during T cell receptor-induced NF-kappaB activation. J Biol Chem. 2011, 286: 7522-7534.PubMedCentralPubMed
43.
Furman JL, Sama DM, Gant JC, Beckett TL, Murphy MP, Bachstetter AD, Van Eldik LJ, Norris CM: Targeting astrocytes ameliorates neurologic changes in a mouse model of Alzheimer’s disease. J Neurosci. 2012, 32: 16129-16140.PubMedCentralPubMed
44.
Canellada A, Ramirez BG, Minami T, Redondo JM, Cano E: Calcium/calcineurin signaling in primary cortical astrocyte cultures: Rcan1-4 and cyclooxygenase-2 as NFAT target genes. Glia. 2008, 56: 709-722.PubMed
45.
Fernandez AM, Fernandez S, Carrero P, Garcia-Garcia M, Torres-Aleman I: Calcineurin in reactive astrocytes plays a key role in the interplay between proinflammatory and anti-inflammatory signals. J Neurosci. 2007, 27: 8745-8756.PubMed
46.
Leal RB, Frizzo JK, Tramontina F, Fieuw-Makaroff S, Bobrovskaya L, Dunkley PR, Goncalves CA: S100B protein stimulates calcineurin activity. Neuroreport. 2004, 15: 317-320.PubMed
47.
Perez-Ortiz JM, Serrano-Perez MC, Pastor MD, Martin ED, Calvo S, Rincon M, Tranque P: Mechanical lesion activates newly identified NFATc1 in primary astrocytes: implication of ATP and purinergic receptors. Eur J Neurosci. 2008, 27: 2453-2465.PubMed
48.
Furman JL, Artiushin IA, Norris CM: Disparate effects of serum on basal and evoked NFAT activity in primary astrocyte cultures. Neurosci Lett. 2010, 469: 365-369.PubMedCentralPubMed
49.
Blalock EM, Chen KC, Sharrow K, Herman JP, Porter NM, Foster TC, Landfield PW: Gene microarrays in hippocampal aging: statistical profiling identifies novel processes correlated with cognitive impairment. J Neurosci. 2003, 23: 3807-3819.PubMed
50.
Blalock EM, Geddes JW, Chen KC, Porter NM, Markesbery WR, Landfield PW: Incipient Alzheimer’s disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci U S A. 2004, 101: 2173-2178.PubMedCentralPubMed
51.
Kadish I, Thibault O, Blalock EM, Chen KC, Gant JC, Porter NM, Landfield PW: Hippocampal and cognitive aging across the lifespan: a bioenergetic shift precedes and increased cholesterol trafficking parallels memory impairment. J Neurosci. 2009, 29: 1805-1816.PubMedCentralPubMed
52.
Wilcock DM: Neuroinflammatory phenotypes and their roles in Alzheimer’s disease. Neurodegener Dis. 2014, 13: 183-185.PubMed
53.
Mrak RE, Griffin WS: The role of activated astrocytes and of the neurotrophic cytokine S100B in the pathogenesis of Alzheimer’s disease. Neurobiol Aging. 2001, 22: 915-922.PubMed
54.
Mrak RE, Griffin WS: Glia and their cytokines in progression of neurodegeneration. Neurobiol Aging. 2005, 26: 349-354.PubMed
55.
Griffin WS, Sheng JG, Royston MC, Gentleman SM, McKenzie JE, Graham DI, Roberts GW, Mrak RE: Glial-neuronal interactions in Alzheimer’s disease: the potential role of a `cytokine cycle’ in disease progression. Brain Pathol. 1998, 8: 65-72.PubMed
56.
Nagamoto-Combs K, Combs CK: Microglial phenotype is regulated by activity of the transcription factor, NFAT (nuclear factor of activated T cells). J Neurosci. 2010, 30: 9641-9646.PubMedCentralPubMed
57.
Kataoka A, Tozaki-Saitoh H, Koga Y, Tsuda M, Inoue K: Activation of P2X7 receptors induces CCL3 production in microglial cells through transcription factor NFAT. J Neurochem. 2009, 108: 115-125.PubMed
58.
Shiratori M, Tozaki-Saitoh H, Yoshitake M, Tsuda M, Inoue K: P2X7 receptor activation induces CXCL2 production in microglia through NFAT and PKC/MAPK pathways. J Neurochem. 2010, 114: 810-819.PubMed
59.
Kim B, Jeong HK, Kim JH, Lee SY, Jou I, Joe EH: Uridine 5’-diphosphate induces chemokine expression in microglia and astrocytes through activation of the P2Y6 receptor. J Immunol. 2011, 186: 3701-3709.PubMed
60.
Im SH, Rao A: Activation and deactivation of gene expression by Ca2+/calcineurin-NFAT-mediated signaling.Mol Cells 2004, 18:1-9..
61.
Rudensky AY, Gavin M, Zheng Y: FOXP3 and NFAT: partners in tolerance. Cell. 2006, 126: 253-256.PubMed
62.
Wu Y, Borde M, Heissmeyer V, Feuerer M, Lapan AD, Stroud JC, Bates DL, Guo L, Han A, Ziegler SF, Mathis D, Benoist C, Chen L, Rao A: FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell. 2006, 126: 375-387.PubMed
63.
Fernandez AM, Jimenez S, Mecha M, Davila D, Guaza C, Vitorica J, Torres-Aleman I: Regulation of the phosphatase calcineurin by insulin-like growth factor I unveils a key role of astrocytes in Alzheimer’s pathology. Mol Psychiatry. 2012, 17: 705-718.PubMed
64.
Abbott KL, Friday BB, Thaloor D, Murphy TJ, Pavlath GK: Activation and cellular localization of the cyclosporine A-sensitive transcription factor NF-AT in skeletal muscle cells. Mol Biol Cell. 1998, 9: 2905-2916.PubMedCentralPubMed
65.
Calabria E, Ciciliot S, Moretti I, Garcia M, Picard A, Dyar KA, Pallafacchina G, Tothova J, Schiaffino S, Murgia M: NFAT isoforms control activity-dependent muscle fiber type specification. Proc Natl Acad Sci U S A. 2009, 106: 13335-13340.PubMedCentralPubMed
66.
Jin SM, Cho HJ, Kim YW, Hwang JY, Mook-Jung I: Abeta-induced Ca(2+) influx regulates astrocytic BACE1 expression via calcineurin/NFAT4 signals. Biochem Biophys Res Commun. 2012, 425: 649-655.PubMed
67.
Serrano-Perez MC, Martin ED, Vaquero CF, Azcoitia I, Calvo S, Cano E, Tranque P: Response of transcription factor NFATc3 to excitotoxic and traumatic brain insults: identification of a subpopulation of reactive astrocytes. Glia. 2011, 59: 94-107.PubMed
68.
Yan HQ, Shin SS, Ma X, Li Y, Dixon CE: Differential effect of traumatic brain injury on the nuclear factor of activated T Cells C3 and C4 isoforms in the rat hippocampus. Brain Res. 2014, 1548: 63-72.PubMedCentralPubMed
69.
Luoma JI, Zirpel L: Deafferentation-induced activation of NFAT (nuclear factor of activated T-cells) in cochlear nucleus neurons during a developmental critical period: a role for NFATc4-dependent apoptosis in the CNS. J Neurosci. 2008, 28: 3159-3169.PubMed
70.
Shioda N, Han F, Moriguchi S, Fukunaga K: Constitutively active calcineurin mediates delayed neuronal death through Fas-ligand expression via activation of NFAT and FKHR transcriptional activities in mouse brain ischemia. J Neurochem. 2007, 102: 1506-1517.PubMed
71.
Hudry E, Wu HY, Arbel-Ornath M, Hashimoto T, Matsouaka R, Fan Z, Spires-Jones TL, Betensky RA, Bacskai BJ, Hyman BT: Inhibition of the NFAT pathway alleviates amyloid beta neurotoxicity in a mouse model of Alzheimer’s disease. J Neurosci. 2012, 32: 3176-3192.PubMedCentralPubMed
72.
Yamaguchi R, Hosaka M, Torii S, Hou N, Saito N, Yoshimoto Y, Imai H, Takeuchi T: Cyclophilin C-associated protein regulation of phagocytic functions via NFAT activation in macrophages. Brain Res. 2011, 1397: 55-65.PubMed
73.
Neria F, del Carmen S-PM, Velasco P, Urso K, Tranque P, Cano E: NFATc3 promotes Ca(2+) -dependent MMP3 expression in astroglial cells. Glia. 2013, 61: 1052-1066.PubMed
74.
Rojanathammanee L, Puig KL, Combs CK: Pomegranate polyphenols and extract inhibit nuclear factor of activated T-cell activity and microglial activation in vitro and in a transgenic mouse model of Alzheimer disease. J Nutr. 2013, 143: 597-605.PubMedCentralPubMed
75.
Maragakis NJ, Rothstein JD: Glutamate transporters: animal models to neurologic disease. Neurobiol Dis. 2004, 15: 461-473.PubMed
76.
Sultana R, Butterfield DA: Alterations of some membrane transport proteins in Alzheimer’s disease: role of amyloid beta-peptide. Mol Biosyst. 2008, 4: 36-41.PubMed
77.
Scimemi A, Meabon JS, Woltjer RL, Sullivan JM, Diamond JS, Cook DG: Amyloid-beta1-42 slows clearance of synaptically released glutamate by mislocalizing astrocytic GLT-1. J Neurosci. 2013, 33: 5312-5318.PubMedCentralPubMed
78.
Matos M, Augusto E, Machado NJ, dos Santos-Rodrigues A, Cunha RA, Agostinho P: Astrocytic adenosine A2A receptors control the amyloid-beta peptide-induced decrease of glutamate uptake. J Alzheimers Dis. 2012, 31: 555-567.PubMed
79.
Schallier A, Smolders I, Van Dam D, Loyens E, De Deyn PP, Michotte A, Michotte Y, Massie A: Region- and age-specific changes in glutamate transport in the AbetaPP23 mouse model for Alzheimer’s disease. J Alzheimers Dis. 2011, 24: 287-300.PubMed
80.
Tian G, Kong Q, Lai L, Ray-Chaudhury A, Lin CL: Increased expression of cholesterol 24S-hydroxylase results in disruption of glial glutamate transporter EAAT2 association with lipid rafts: a potential role in Alzheimer’s disease. J Neurochem. 2010, 113: 978-989.PubMedCentralPubMed
81.
Matos M, Augusto E, Oliveira CR, Agostinho P: Amyloid-beta peptide decreases glutamate uptake in cultured astrocytes: involvement of oxidative stress and mitogen-activated protein kinase cascades. Neuroscience. 2008, 156: 898-910.PubMed
82.
Jacob CP, Koutsilieri E, Bartl J, Neuen-Jacob E, Arzberger T, Zander N, Ravid R, Roggendorf W, Riederer P, Grunblatt E: Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer’s disease. J Alzheimers Dis. 2007, 11: 97-116.PubMed
83.
Lauderback CM, Hackett JM, Huang FF, Keller JN, Szweda LI, Markesbery WR, Butterfield DA: The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer’s disease brain: the role of Abeta1-42. J Neurochem. 2001, 78: 413-416.PubMed
84.
Katagiri H, Tanaka K, Manabe T: Requirement of appropriate glutamate concentrations in the synaptic cleft for hippocampal LTP induction. Eur J Neurosci. 2001, 14: 547-553.PubMed
85.
Rothstein JD, Dykes-Hoberg M, Pardo CA, Bristol LA, Jin L, Kuncl RW, Kanai Y, Hediger MA, Wang Y, Schielke JP, Welty DF: Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron. 1996, 16: 675-686.PubMed
86.
Mookherjee P, Green PS, Watson GS, Marques MA, Tanaka K, Meeker KD, Meabon JS, Li N, Zhu P, Olson VG, Cook DG: GLT-1 loss accelerates cognitive deficit onset in an Alzheimer’s disease animal model. J Alzheimers Dis. 2011, 26: 447-455.PubMedCentralPubMed
87.
Simpson JE, Ince PG, Lace G, Forster G, Shaw PJ, Matthews F, Savva G, Brayne C, Wharton SB: Astrocyte phenotype in relation to Alzheimer-type pathology in the ageing brain. Neurobiol Aging. 2010, 31 (4): 578-590.PubMed
88.
Fang J, Han D, Hong J, Tan Q, Tian Y: The chemokine, macrophage inflammatory protein-2gamma, reduces the expression of glutamate transporter-1 on astrocytes and increases neuronal sensitivity to glutamate excitotoxicity. J Neuroinflammation. 2012, 9: 267.PubMedCentralPubMed
89.
Boycott HE, Wilkinson JA, Boyle JP, Pearson HA, Peers C: Differential involvement of TNF alpha in hypoxic suppression of astrocyte glutamate transporters. Glia. 2008, 56: 998-1004.PubMed
90.
Fine SM, Angel RA, Perry SW, Epstein LG, Rothstein JD, Dewhurst S, Gelbard HA: Tumor necrosis factor alpha inhibits glutamate uptake by primary human astrocytes. Implications for pathogenesis of HIV-1 dementia. J Biol Chem. 1996, 271: 15303-15306.PubMed
91.
Tilleux S, Hermans E: Neuroinflammation and regulation of glial glutamate uptake in neurological disorders. J Neurosci Res. 2007, 85: 2059-2070.PubMed
92.
Su ZZ, Leszczyniecka M, Kang DC, Sarkar D, Chao W, Volsky DJ, Fisher PB: Insights into glutamate transport regulation in human astrocytes: cloning of the promoter for excitatory amino acid transporter 2 (EAAT2). Proc Natl Acad Sci U S A. 2003, 100: 1955-1960.PubMedCentralPubMed
93.
De Bock M, Decrock E, Wang N, Bol M, Vinken M, Bultynck G, Leybaert L: The dual face of connexin-based astroglial Ca2+communication: a key player in brain physiology and a prime target in pathology.Biochim Biophys Acta 2014, 1843(10):2211-2232..
94.
95.
Lutz SE, Zhao Y, Gulinello M, Lee SC, Raine CS, Brosnan CF: Deletion of astrocyte connexins 43 and 30 leads to a dysmyelinating phenotype and hippocampal CA1 vacuolation. J Neurosci. 2009, 29: 7743-7752.PubMedCentralPubMed
96.
Wallraff A, Kohling R, Heinemann U, Theis M, Willecke K, Steinhauser C: The impact of astrocytic gap junctional coupling on potassium buffering in the hippocampus. J Neurosci. 2006, 26: 5438-5447.PubMed
97.
Theis M, Jauch R, Zhuo L, Speidel D, Wallraff A, Doring B, Frisch C, Sohl G, Teubner B, Euwens C, Huston J, Steinhäuser C, Messing A, Heinemann U, Willecke K: Accelerated hippocampal spreading depression and enhanced locomotory activity in mice with astrocyte-directed inactivation of connexin43. J Neurosci. 2003, 23: 766-776.PubMed
98.
Lin JH, Weigel H, Cotrina ML, Liu S, Bueno E, Hansen AJ, Hansen TW, Goldman S, Nedergaard M: Gap-junction-mediated propagation and amplification of cell injury. Nat Neurosci. 1998, 1: 494-500.PubMed
99.
Kielian T, Esen N: Effects of neuroinflammation on glia-glia gap junctional intercellular communication: a perspective. Neurochem Int. 2004, 45: 429-436.PubMed
100.
Orellana JA, Martinez AD, Retamal MA: Gap junction channels and hemichannels in the CNS: regulation by signaling molecules. Neuropharmacology. 2013, 75: 567-582.PubMed
101.
Lampe PD, Lau AF: The effects of connexin phosphorylation on gap junctional communication. Int J Biochem Cell Biol. 2004, 36: 1171-1186.PubMedCentralPubMed
102.
Li WE, Nagy JI: Connexin43 phosphorylation state and intercellular communication in cultured astrocytes following hypoxia and protein phosphatase inhibition. Eur J Neurosci. 2000, 12: 2644-2650.PubMed
103.
Tence M, Ezan P, Amigou E, Giaume C: Increased interaction of connexin43 with zonula occludens-1 during inhibition of gap junctions by G protein-coupled receptor agonists. Cell Signal. 2012, 24: 86-98.PubMed
104.
Furman JL, Mohmmad Abdul H, Norris CM: Alterations in connexin 43 phosphorylation during the progression of Alzheimer’s disease: possible role of astrocytic calcineurin. Alzheimers Dement. 2012, 8: P300.
105.
Kuchibhotla KV, Lattarulo CR, Hyman BT, Bacskai BJ: Synchronous hyperactivity and intercellular calcium waves in astrocytes in Alzheimer mice. Science. 2009, 323: 1211-1215.PubMedCentralPubMed
106.
Lin DT, Wu J, Holstein D, Upadhyay G, Rourk W, Muller E, Lechleiter JD: Ca2+signaling, mitochondria and sensitivity to oxidative stress in aging astrocytes.Neurobiol Aging 2007, 28:99-111..
107.
Sama DM, Norris CM: Calcium dysregulation and neuroinflammation: discrete and integrated mechanisms for age-related synaptic dysfunction. Ageing Res Rev. 2013, 12: 982-995.PubMed
108.
Carafoli E, Genazzani A, Geurini D: Calcium controls the transcription of its own transporters and channels in developing neurons. Biochem Biophys Res Comm. 1999, 266: 624-632.PubMed
109.
Genazzani AA, Carafoli E, Guerini D: Calcineurin controls inositol 1,4,5-trisphosphate type 1 receptor expression in neurons. Proc Natl Acad Sci U S A. 1999, 96: 5797-5801.PubMedCentralPubMed
110.
Graef IA, Mermelstein PG, Stankunas K, Neilson JR, Deisseroth K, Tsien RW, Crabtree GR: L-type calcium channels and GSK-3 regulate the activity of NF-ATc4 in hippocampal neurons. Nature. 1999, 401: 703-708.PubMed
111.
Groth RD, Coicou LG, Mermelstein PG, Seybold VS: Neurotrophin activation of NFAT-dependent transcription contributes to the regulation of pro-nociceptive genes. J Neurochem. 2007, 102: 1162-1174.PubMed
112.
Grolla AA, Fakhfouri G, Balzaretti G, Marcello E, Gardoni F, Canonico PL, DiLuca M, Genazzani AA, Lim D: AΒ leads to Ca2+ signaling alterations and transcriptional changes in glial cells.Neurobiol Aging 2013, 34:511-522..PubMed
113.
Norris CM, Blalock EM, Chen KC, Porter NM, Landfield PW: Calcineurin enhances L-type Ca2+ channel activity in hippocampal neurons: increased effect with age in culture.Neuroscience 2002, 110:213-225..PubMedCentralPubMed
114.
Norris CM, Blalock EM, Chen KC, Porter NM, Thibault O, Kraner SD, Landfield PW: Hippocampal `zipper’ slice studies reveal a necessary role for calcineurin in the increased activity of L-type Ca2+channels with aging. Neurobiol Aging 2010, 31:328-338..PubMedCentralPubMed
115.
Yatani A, Honda R, Tymitz KM, Lalli MJ, Molkentin JD: Enhanced Ca2+ channel currents in cardiac hypertrophy induced by activation of calcineurin-dependent pathway. J Mol Cell Cardiol 2001, 33:249-259..PubMed
116.
Tandan S, Wang Y, Wang TT, Jiang N, Hall DD, Hell JW, Luo X, Rothermel BA, Hill JA: Physical and functional interaction between calcineurin and the cardiac L-type Ca2+ channel. Circ Res 2009, 105:51-60..PubMedCentralPubMed
117.
Westenbroek RE, Bausch SB, Lin RC, Franck JE, Noebels JL, Catterall WA: Upregulation of L-type Ca2+ channels in reactive astrocytes after brain injury, hypomyelination, and ischemia. J Neurosci 1998, 18:2321-2334..PubMed
118.
Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL: Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci. 2007, 27: 2866-2875.PubMed
119.
Wu HY, Hudry E, Hashimoto T, Kuchibhotla K, Rozkalne A, Fan Z, Spires-Jones T, Xie H, Arbel-Ornath M, Grosskreutz CL, Bacskai BJ, Hyman BT: Amyloid beta induces the morphological neurodegenerative triad of spine loss, dendritic simplification, and neuritic dystrophies through calcineurin activation. J Neurosci. 2010, 30: 2636-2649.PubMedCentralPubMed
120.
Reese LC, Zhang W, Dineley KT, Kayed R, Taglialatela G: Selective induction of calcineurin activity and signaling by oligomeric amyloid beta. Aging Cell. 2008, 7: 824-835.PubMedCentralPubMed
121.
Zhao WQ, Santini F, Breese R, Ross D, Zhang XD, Stone DJ, Ferrer M, Townsend M, Wolfe AL, Seager MA, Kinney GG, Shughrue PJ, Ray WJ: Inhibition of calcineurin-mediated endocytosis and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors prevents amyloid beta oligomer-induced synaptic disruption. J Biol Chem. 2010, 285: 7619-7632.PubMedCentralPubMed
122.
Kuchibhotla KV, Goldman ST, Lattarulo CR, Wu HY, Hyman BT, Bacskai BJ: Abeta plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron. 2008, 59: 214-225.PubMedCentralPubMed
123.
Agostinho P, Lopes JP, Velez Z, Oliveira CR: Overactivation of calcineurin induced by amyloid-beta and prion proteins. Neurochem Int. 2008, 52: 1226-1233.PubMed
124.
Hong HS, Hwang JY, Son SM, Kim YH, Moon M, Inhee MJ: FK506 reduces amyloid plaque burden and induces MMP-9 in AbetaPP/PS1 double transgenic mice. J Alzheimers Dis. 2010, 22: 97-105.PubMed
125.
Cho HJ, Jin SM, Youn HD, Huh K, Mook-Jung I: Disrupted intracellular calcium regulates BACE1 gene expression via nuclear factor of activated T cells 1 (NFAT 1) signaling. Aging Cell. 2008, 7: 137-147.PubMed
126.
Zhao J, O’Connor T, Vassar R: The contribution of activated astrocytes to Abeta production: implications for Alzheimer’s disease pathogenesis. J Neuroinflammation. 2011, 8: 150.PubMedCentralPubMed
127.
Forloni G, Demicheli F, Giorgi S, Bendotti C, Angeretti N: Expression of amyloid precursor protein mRNAs in endothelial, neuronal and glial cells: modulation by interleukin-1. Brain Res Mol Brain Res. 1992, 16: 128-134.PubMed
128.
Li Y, Wang J, Sheng JG, Liu L, Barger SW, Jones RA, Van Eldik LJ, Mrak RE, Griffin WS: S100 beta increases levels of beta-amyloid precursor protein and its encoding mRNA in rat neuronal cultures. J Neurochem. 1998, 71: 1421-1428.PubMed
129.
Sastre Ml Dewachter I, Landreth GE, Willson TM, Klockgether T, van Leuven F, Heneka MT: Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J Neurosci. 2003, 23: 9796-9804.PubMed
130.
Yamamoto M, Kiyota T, Horiba M, Buescher JL, Walsh SM, Gendelman HE, Ikezu T: Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice. Am J Pathol. 2007, 170: 680-692.PubMedCentralPubMed
131.
Sutinen EM, Pirttilä T, Anderson G, Salminen A, Ojala JO: Pro-inflammatory interleukin-18 increases Alzheimer’s disease-associated amyloid- β production in human neuron-like cells. J Neuroinflammation. 2012, 9: 199.PubMedCentralPubMed
132.
Chen XH, Siman R, Iwata A, Meaney DF, Trojanowski JQ, Smith DH: Long-term accumulation of amyloid-beta, beta-secretase, presenilin-1, and caspase-3 in damaged axons following brain trauma. Am J Pathol. 2004, 165: 357-371.PubMedCentralPubMed
133.
Pierrot N, Ghisdal P, Caumont AS, Octave JN: Intraneuronal amyloid-beta1-42 production triggered by sustained increase of cytosolic calcium concentration induces neuronal death. J Neurochem. 2004, 88: 1140-1150.PubMed
134.
Chen XH, Johnson VE, Uryu K, Trojanowski JQ, Smith DH: A lack of amyloid beta plaques despite persistent accumulation of amyloid beta in axons of long-term survivors of traumatic brain injury. Brain Pathol. 2009, 19: 214-223.PubMedCentralPubMed
135.
Alley GM, Bailey JA, Chen D, Ray B, Puli LK, Tanila H, Banerjee PK, Lahiri DK: Memantine lowers amyloid-beta peptide levels in neuronal cultures and in APP/PS1 transgenic mice. J Neurosci Res. 2010, 88: 143-154.PubMedCentralPubMed
136.
Marklund N, Farrokhnia N, Hånell A, Vanmechelen E, Enblad P, Zetterberg H, Blennow K, Hillered L: Monitoring of β-amyloid dynamics after human traumatic brain injury. J Neurotrauma. 2014, 31: 42-55.PubMed
Metadata
Title
Calcineurin and glial signaling: neuroinflammation and beyond
Authors
Jennifer L Furman
Christopher M Norris
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Journal of Neuroinflammation / Issue 1/2014
Electronic ISSN: 1742-2094
DOI
https://doi.org/10.1186/s12974-014-0158-7

Other articles of this Issue 1/2014

Journal of Neuroinflammation 1/2014 Go to the issue

Research

Molecular profile of cochlear immunity in the resident cells of the organ of Corti

Research

CXCL13 and neopterin concentrations in cerebrospinal fluid of patients with Lyme neuroborreliosis and other diseases that cause neuroinflammation

Research

Metabolic consequences of interleukin-6 challenge in developing neurons and astroglia

Research

NFκB-mediated CXCL1 production in spinal cord astrocytes contributes to the maintenance of bone cancer pain in mice

Research

Immune responses in rapidly progressive dementia: a comparative study of neuroinflammatory markers in Creutzfeldt-Jakob disease, Alzheimer's disease and multiple sclerosis

Research

FGF-2 released from degenerating neurons exerts microglial-induced neuroprotection via FGFR3-ERK signaling pathway